[go: up one dir, main page]

CY1115333T1 - K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος - Google Patents

K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος

Info

Publication number
CY1115333T1
CY1115333T1 CY20141100291T CY141100291T CY1115333T1 CY 1115333 T1 CY1115333 T1 CY 1115333T1 CY 20141100291 T CY20141100291 T CY 20141100291T CY 141100291 T CY141100291 T CY 141100291T CY 1115333 T1 CY1115333 T1 CY 1115333T1
Authority
CY
Cyprus
Prior art keywords
treatment
ras
methods
egfr
diagnostic treatments
Prior art date
Application number
CY20141100291T
Other languages
English (en)
Inventor
Daniel Freeman
Todd Juan
Robert Radinsky
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115333(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1115333T1 publication Critical patent/CY1115333T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα δήλωση αφορά σε K-ras μεταλλάξεις, σε πολυνουκλεοτίδια που κωδικοποιούν μεταλλακτικά K-ras πολυπεπτίδια και σε μεθόδους πιστοποίησης K-ras μεταλλάξεων. Η παρούσα δήλωση επίσης αφορά σε μεθόδους διάγνωσης καρκίνου και μεθόδους και κιτ για πρόβλεψη της χρησιμότητας των παραγόντων ειδικής σύνδεσης αντι-EGFr στην θεραπεία όγκων.
CY20141100291T 2007-03-13 2014-04-16 K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος CY1115333T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13
EP08742061.8A EP2121989B2 (en) 2007-03-13 2008-03-11 K-ras mutations and anti-egfr antibody therapy

Publications (1)

Publication Number Publication Date
CY1115333T1 true CY1115333T1 (el) 2017-01-04

Family

ID=39689242

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100291T CY1115333T1 (el) 2007-03-13 2014-04-16 K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
CY20171100792T CY1119112T1 (el) 2007-03-13 2017-07-25 K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100792T CY1119112T1 (el) 2007-03-13 2017-07-25 K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος

Country Status (21)

Country Link
US (3) US20080293055A1 (el)
EP (2) EP2121989B2 (el)
JP (1) JP2010521153A (el)
AR (1) AR065687A1 (el)
AU (1) AU2008226803A1 (el)
CA (1) CA2680326A1 (el)
CL (1) CL2008000717A1 (el)
CY (2) CY1115333T1 (el)
DK (2) DK2465950T3 (el)
ES (2) ES2458626T5 (el)
HR (2) HRP20140360T4 (el)
HU (1) HUE033695T2 (el)
LT (1) LT2465950T (el)
MX (1) MX2009009787A (el)
PE (1) PE20081880A1 (el)
PL (2) PL2121989T5 (el)
PT (2) PT2465950T (el)
RS (2) RS56422B1 (el)
SI (2) SI2465950T1 (el)
TW (1) TW200902553A (el)
WO (1) WO2008112269A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
DK2412828T3 (da) * 2007-03-13 2013-09-02 Amgen Inc K-ras og B-raf-mutationer og anti-EGFr-antistofbehandling
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
CN102301002A (zh) 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
NZ602920A (en) * 2010-04-12 2014-07-25 Response Genetics Inc Kras primers and probes
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
CN104039328B (zh) * 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
EP4424826A3 (en) 2012-09-04 2024-11-27 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
SG11201507739TA (en) * 2013-03-19 2015-10-29 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
SG11201604923XA (en) 2013-12-28 2016-07-28 Guardant Health Inc Methods and systems for detecting genetic variants
WO2015175705A1 (en) * 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
JP2019507585A (ja) 2015-12-17 2019-03-22 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａの分析による腫瘍遺伝子コピー数を決定するための方法
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
EP0636186B1 (en) 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Probe composition and method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1161563A2 (en) 1999-03-15 2001-12-12 PE Corporation (NY) Probe/mobility modifier complexes for multiplex nucleic acid detection
CA2410950A1 (en) 2000-05-30 2001-12-06 Hans-Michael Wenz Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
WO2004111273A2 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
KR101289774B1 (ko) 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
US7932026B2 (en) * 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
US20060141497A1 (en) * 2004-10-22 2006-06-29 Finkelstein Sydney D Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
KR20080014745A (ko) 2005-04-01 2008-02-14 암젠 인코포레이티드 상피세포 성장인자 수용체 유전자 복제 수
JP2008535508A (ja) * 2005-04-14 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法
SI1913157T2 (sl) * 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
JP2009505658A (ja) 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008033442A2 (en) * 2006-09-12 2008-03-20 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
DK2412828T3 (da) * 2007-03-13 2013-09-02 Amgen Inc K-ras og B-raf-mutationer og anti-EGFr-antistofbehandling

Also Published As

Publication number Publication date
US10030270B2 (en) 2018-07-24
CA2680326A1 (en) 2008-09-18
CL2008000717A1 (es) 2008-09-22
WO2008112269A2 (en) 2008-09-18
LT2465950T (lt) 2017-10-10
US20190048423A1 (en) 2019-02-14
ES2458626T5 (es) 2022-04-29
JP2010521153A (ja) 2010-06-24
DK2121989T3 (da) 2014-04-28
EP2121989B2 (en) 2022-03-09
AR065687A1 (es) 2009-06-24
DK2465950T3 (en) 2017-10-09
WO2008112269A3 (en) 2008-11-20
SI2121989T1 (sl) 2014-06-30
EP2465950B1 (en) 2017-07-12
HRP20171509T1 (hr) 2017-11-17
SI2121989T2 (sl) 2022-05-31
EP2121989B1 (en) 2014-01-22
PT2465950T (pt) 2017-10-17
ES2458626T3 (es) 2014-05-06
PL2121989T3 (pl) 2014-07-31
PL2465950T3 (pl) 2017-12-29
SI2465950T1 (sl) 2017-11-30
EP2465950A2 (en) 2012-06-20
AU2008226803A1 (en) 2008-09-18
EP2465950A3 (en) 2013-03-13
MX2009009787A (es) 2009-09-22
US20120264129A1 (en) 2012-10-18
HUE033695T2 (en) 2017-12-28
CY1119112T1 (el) 2018-02-14
US11155876B2 (en) 2021-10-26
DK2121989T4 (da) 2022-06-20
EP2121989A2 (en) 2009-11-25
HRP20140360T1 (hr) 2014-05-23
RS53265B (sr) 2014-08-29
RS53265B2 (sr) 2022-06-30
PE20081880A1 (es) 2008-12-31
HRP20140360T4 (hr) 2022-06-10
TW200902553A (en) 2009-01-16
PL2121989T5 (pl) 2023-03-06
PT2121989E (pt) 2014-04-30
US20080293055A1 (en) 2008-11-27
ES2635051T3 (es) 2017-10-02
RS56422B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
CY1114159T1 (el) K-ras και b-raf μεταλλαξεις και αντι-egfr θεραπεια με αντισωματα
TW200806322A (en) Diagnostics and treatments for tumors
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
AR064458A1 (es) Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
PH12015501134A1 (en) Egfr and c-met-fibronectin type iii domain binding molecules
CY1113637T1 (el) Ενωση αμινο πυραζολης
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
TW200716141A (en) Compositions and methods for treatment for neoplasms
WO2008101118A3 (en) A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
MX2008007502A (es) Anticuerpos anti mn y metodos para su utilizacion.
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
MX2010004259A (es) Tratamientos antitumorales mejorados.
ITRM20040098A1 (it) Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3